English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 855450      Online Users : 1120
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version
    國家衛生研究院 NHRI > 癌症研究所 > 其他 > 期刊論文 >  Item 3990099045/4386


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/4386


    Title: Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial
    Authors: Hsu, C;Kuo, SH;Hu, FC;Cheng, AL;Shih, JY;Yu, CJ;Lin, CC;Huang, TC;Yang, PC;Yang, CH
    Contributors: National Institute of Cancer Research
    Abstract: Background: Epirubicin was effective for the treatment of non-small cell lung carcinoma (NSCLC). This study compared the efficacy and safety of gemcitabine plus conventional-dose epirubicin (GE) with gemcitabine-cisplatin (GC) as first-line chemotherapy for stage IIIB/IV NSCLC and evaluated the predictive value of nuclear expression of excision repair cross-complementing group 1 (ERCC1) and topoisomerase II alpha (Topolla) on treatment outcome. Patients and methods: Patients were randomized to GE (gemcitabine, 1000 mg/m(2) on days 1, 8, and 15 and epirubicin, 70 mg/m(2) on day 15) or GC (gemcitabine, 1000 mg/m(2) on days 1, 8, and 15 and cisptatin, 80 mg/m(2) on day 15). Treatment cycles were repeated every 4 weeks. Immunohistochemical study of ERCC1 and TopoII alpha was done for patients with available tumor specimens. Results: The response rate was 31.0% (95% CI 16.4-45.5%) for GC (n = 41) and 37.2.0% (95% CI 22.2-52.3%) for GE (n = 39). No significant differences in median time-to-treatment-failure (TTF) (GC, 6.1 months; GE, 6.2 months) or overall survival (GC, 13.2 months; GE, 21.5 months) were found between the two arms. Grade 3/4 neutropenia and febrile neutropenia were more common in GE. However, delay of protocol treatment due to leukopenia was similar between the two arms. Patients with expression of both ERCC1 and TopoII alpha had a significantly shorter TTF (median 2.4 months, 95% CI 0.7-4.1 months) than other patients (median 8.8 months, 95% CI 5.8-11.8 months) (p=0.04). Conclusion: GE regimen is effective and well-tolerated for NSCLC patients. Expression of both ERCC1 and TopoII alpha may be associated with poor response to chemotherapy.
    Date: 2008-12
    Relation: Lung Cancer. 2008 Dec;62(3):334-343.
    Link to: http://dx.doi.org/10.1016/j.lungcan.2008.03.010
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0169-5002&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000262217700009
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=45849137388
    Appears in Collections:[其他] 期刊論文

    Files in This Item:

    File Description SizeFormat
    ISI000262217700009.pdf505KbAdobe PDF590View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback